ArticleOncotarget2017
Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Protein Induced by Vitamin K Absence or Antagonist II in Primary Liver Cancer: Basic Research Insights and Clinical Applications.Journal of clinical and translational hepatology · 2025Review
- Risk Factors for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Hepatocellular Carcinoma.Digestive diseases and sciences · 2025Article
- Enhancement of treatment efficacy of hepatic tumours using Trans-arterial-chemoembolization.American journal of cancer research · 2023Review
- Revisiting artificial intelligence diagnosis of hepatocellular carcinoma with DIKWH framework.Frontiers in genetics · 2023Review
- The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data.Journal of clinical laboratory analysis · 2021Article
- Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients.World journal of gastroenterology · 2020Article
- Autoantibodies against tumor-associated antigens combined with microRNAs in detecting esophageal squamous cell carcinoma.Cancer medicine · 2020Observational
- Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2020Review
- BiomarkersWorld journal of clinical cases · 2019Review
- Status of, and strategies for improving, adherence to HCC screening and surveillance.Journal of hepatocellular carcinoma · 2019Review
- Identification of long non-coding RNABioscience reports · 2018Article
- Integrated Artificial Intelligence Approaches for Disease Diagnostics.Indian journal of microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than 70% of hepatocellular carcinoma (HCC) cases develop as a consequence of liver cirrhosis (LC). Here we have evaluated the diagnostic potential of four serum biomarkers, and developed models for HCC diagnosis and differentiation from LC patients. Serum levels of α-fetoprotein (AFP), AFP-L3, des-γ-carboxy prothrombin (DCP), and Golgi protein 73 (GP73) were analyzed in 114 advanced HCC patients, 81 early stage HCC patients, and 152 LC patients. Multilayer perceptron (MLP) and radial basis function (RBF) neural networks were used to construct the diagnostic models. Using all stages, HCC diagnostic models had a higher sensitivity (>70%) than the individual serum biomarkers, whereas only early stage HCC diagnostic models had a higher specificity (>80%). The early stage HCC diagnostic models could not be used as HCC screening tools due to their low sensitivity (about 40%). These results suggest that a combination of the two models might be used as a screening tool to distinguish early stage HCC patients from LC patients, thus improving prevention and treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.